GT201000172A - Inhibidores de cinesina como productos terapéuticos para el cáncer - Google Patents
Inhibidores de cinesina como productos terapéuticos para el cáncerInfo
- Publication number
- GT201000172A GT201000172A GT201000172A GT201000172A GT201000172A GT 201000172 A GT201000172 A GT 201000172A GT 201000172 A GT201000172 A GT 201000172A GT 201000172 A GT201000172 A GT 201000172A GT 201000172 A GT201000172 A GT 201000172A
- Authority
- GT
- Guatemala
- Prior art keywords
- inhibitors
- cinesine
- cancer
- compounds
- ksp
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1396607P | 2007-12-14 | 2007-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201000172A true GT201000172A (es) | 2012-04-30 |
Family
ID=40328566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201000172A GT201000172A (es) | 2007-12-14 | 2010-06-14 | Inhibidores de cinesina como productos terapéuticos para el cáncer |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8252832B2 (enExample) |
| EP (1) | EP2229170B1 (enExample) |
| JP (1) | JP5501976B2 (enExample) |
| KR (1) | KR20100098394A (enExample) |
| CN (1) | CN101939005B (enExample) |
| AR (1) | AR069676A1 (enExample) |
| AU (1) | AU2008337570B2 (enExample) |
| BR (1) | BRPI0821248A2 (enExample) |
| CA (1) | CA2708822A1 (enExample) |
| CL (1) | CL2008003707A1 (enExample) |
| CO (1) | CO6290651A2 (enExample) |
| CR (1) | CR11412A (enExample) |
| DO (1) | DOP2010000175A (enExample) |
| EA (1) | EA018014B1 (enExample) |
| EC (1) | ECSP10010248A (enExample) |
| ES (1) | ES2459442T3 (enExample) |
| GE (1) | GEP20125647B (enExample) |
| GT (1) | GT201000172A (enExample) |
| IL (1) | IL205831A0 (enExample) |
| MA (1) | MA31872B1 (enExample) |
| MY (1) | MY150214A (enExample) |
| NI (1) | NI201000091A (enExample) |
| NZ (1) | NZ585142A (enExample) |
| PA (1) | PA8807801A1 (enExample) |
| PE (1) | PE20091451A1 (enExample) |
| SM (1) | SMP201000095B (enExample) |
| TN (1) | TN2010000204A1 (enExample) |
| TW (1) | TW200930704A (enExample) |
| UY (1) | UY31532A1 (enExample) |
| WO (1) | WO2009077448A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
| US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
| US8748626B2 (en) | 2010-04-15 | 2014-06-10 | Novartis Ag | Oxazole and thiazole compounds as KSP inhibitors |
| JP2016516035A (ja) * | 2013-03-15 | 2016-06-02 | ノバルティス アーゲー | 細胞増殖阻害剤およびそれらのコンジュゲート |
| US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| CN105418527A (zh) * | 2015-12-28 | 2016-03-23 | 青岛友诚高新技术有限公司 | 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途 |
| CN105646361B (zh) * | 2016-02-17 | 2017-12-01 | 吉首大学 | 一种2,4,5‑三芳基咪唑型化合物及其制法和用途 |
| JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ） |
| CN106668863B (zh) * | 2017-02-21 | 2019-04-23 | 南方医科大学 | 靶向ktn1治疗皮肤鳞状细胞癌的药物 |
| GB201706162D0 (en) * | 2017-04-19 | 2017-05-31 | Nat Univ Singapore | Compounds |
| CN111954532A (zh) * | 2018-04-13 | 2020-11-17 | 上海交通大学医学院附属瑞金医院 | 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物 |
| CN109646679A (zh) * | 2019-01-28 | 2019-04-19 | 中国科学院长春应用化学研究所 | 铁离子螯合剂及其可药用盐的用途 |
| CN111529526B (zh) * | 2020-04-14 | 2021-04-23 | 广州领晟医疗科技有限公司 | 一种化合物在制备治疗急性胰腺炎的药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ552510A (en) * | 2004-06-18 | 2010-12-24 | Novartis Vaccines & Diagnostic | N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer |
| US7271271B2 (en) | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
| MY147188A (en) | 2005-08-09 | 2012-11-14 | Novartis Ag | Substituted imidazole compounds as ksp inhibitors |
| MX2009007260A (es) | 2007-01-05 | 2009-07-10 | Novartis Ag | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5). |
-
2008
- 2008-11-25 US US12/313,923 patent/US8252832B2/en not_active Expired - Fee Related
- 2008-12-12 AR ARP080105410A patent/AR069676A1/es not_active Application Discontinuation
- 2008-12-12 WO PCT/EP2008/067412 patent/WO2009077448A1/en not_active Ceased
- 2008-12-12 ES ES08863009.0T patent/ES2459442T3/es active Active
- 2008-12-12 NZ NZ585142A patent/NZ585142A/en not_active IP Right Cessation
- 2008-12-12 JP JP2010537460A patent/JP5501976B2/ja not_active Expired - Fee Related
- 2008-12-12 BR BRPI0821248-1A patent/BRPI0821248A2/pt not_active IP Right Cessation
- 2008-12-12 PE PE2008002064A patent/PE20091451A1/es not_active Application Discontinuation
- 2008-12-12 PA PA20088807801A patent/PA8807801A1/es unknown
- 2008-12-12 CA CA2708822A patent/CA2708822A1/en not_active Abandoned
- 2008-12-12 TW TW097148535A patent/TW200930704A/zh unknown
- 2008-12-12 CL CL2008003707A patent/CL2008003707A1/es unknown
- 2008-12-12 EA EA201000900A patent/EA018014B1/ru not_active IP Right Cessation
- 2008-12-12 GE GEAP200811846A patent/GEP20125647B/en unknown
- 2008-12-12 KR KR1020107012912A patent/KR20100098394A/ko not_active Withdrawn
- 2008-12-12 CN CN200880120667.8A patent/CN101939005B/zh not_active Expired - Fee Related
- 2008-12-12 MY MYPI2010002030A patent/MY150214A/en unknown
- 2008-12-12 AU AU2008337570A patent/AU2008337570B2/en not_active Ceased
- 2008-12-12 EP EP08863009.0A patent/EP2229170B1/en active Active
- 2008-12-15 UY UY31532A patent/UY31532A1/es not_active Application Discontinuation
-
2010
- 2010-05-05 CR CR11412A patent/CR11412A/es not_active Application Discontinuation
- 2010-05-07 TN TN2010000204A patent/TN2010000204A1/fr unknown
- 2010-05-17 IL IL205831A patent/IL205831A0/en unknown
- 2010-05-31 MA MA32879A patent/MA31872B1/fr unknown
- 2010-06-02 NI NI201000091A patent/NI201000091A/es unknown
- 2010-06-10 CO CO10070369A patent/CO6290651A2/es not_active Application Discontinuation
- 2010-06-11 DO DO2010000175A patent/DOP2010000175A/es unknown
- 2010-06-14 GT GT201000172A patent/GT201000172A/es unknown
- 2010-06-14 EC EC2010010248A patent/ECSP10010248A/es unknown
- 2010-07-13 SM SM201000095T patent/SMP201000095B/it unknown
-
2012
- 2012-07-11 US US13/546,713 patent/US8664256B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201000172A (es) | Inhibidores de cinesina como productos terapéuticos para el cáncer | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| ECSP22029777A (es) | Heterociclos bic?clicos como inhibidores de fgfr | |
| GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
| ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
| CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
| ECSP22098041A (es) | Inhibidores alostéricos de egfr y métodos de uso de estos | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| MX2021007426A (es) | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina. | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| CR20240533A (es) | Macrociclos de indazol y su uso | |
| MX2024014995A (es) | Macrociclos que contienen indazol y su uso | |
| BR112017022296A2 (pt) | métodos para tratar câncer | |
| WO2020106751A8 (en) | Inhibitors of gli1 as therapeutic agents | |
| CO2022017969A2 (es) | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 | |
| CU20100121A7 (es) | Inhibidores de cinesina como productos terapéuticos para el cáncer | |
| AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
| AR132459A1 (es) | Inhibidores de kras de pirrolidina | |
| CO2019001967A2 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| DOP2009000143A (es) | Quinazolinas para la inhibicion de pdk1 | |
| CU20100005A7 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas |